Janux Therapeutics, Inc.
JANX
$29.69
$1.003.49%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -18.36% | 3.30% | 34.97% | 17.16% | 7.56% |
| Total Depreciation and Amortization | 5.37% | 13.79% | 31.28% | 67.68% | 132.46% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 82.15% | 68.12% | -19.10% | -16.94% | -18.00% |
| Change in Net Operating Assets | 110.45% | 98.57% | -583.90% | -280.62% | -253.27% |
| Cash from Operations | 13.37% | 29.66% | 14.41% | -13.66% | -17.83% |
| Capital Expenditure | 80.59% | 75.46% | 76.53% | 69.40% | 71.30% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -554.90% | -454.11% | -1,180.44% | -696.39% | -160.80% |
| Cash from Investing | -526.36% | -420.81% | -1,400.51% | -892.01% | -170.70% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,097.75% | 455.81% | 16,532.27% | 18,184.70% | 11,809.60% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 1,097.75% | 455.81% | 16,532.27% | 18,184.70% | 11,809.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,376.81% | 120.17% | 22.91% | 836.45% | -303.36% |